Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen Pharmaceutical Cos.

Division of Johnson & Johnson

Latest From Janssen Pharmaceutical Cos.

Opioid Industry's 'Superstructure' Targeted By State Attorneys General

Janssen, Teva, Allergan, Endo, and Purdue – as well as several distributors – pursued in multistate investigation that follows individual AG inquiries and flurry of state, city, and county suits.

Legal Issues Advertising, Marketing & Sales

Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say

Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.

Biosimilars Medicare

Achillion Keeps Focus On Complement Factor D Inhibitors As J&J Exits HCV

J&J's decision to stop HCV development and end its partnership with Achillion has a ripple effect for the smaller biotech's strategy.

Business Strategies Companies

Rituxan Could Be Top Source Of Price Inflation Rebates In Medicare Part B

HHS Office of Inspector General estimates $1.4bn to $1.8bn could have been saved in Medicare Part B in 2015 if manufacturers provided rebates when drug prices increased faster than inflation.

Pricing Debate Policy
See All

Company Information